Halozyme Therapeutics, Inc. (HALO) financial statements and ratios from SEC XBRL: revenue $1.40B (TTM), net margin 22.7%, revenue growth 47.7% YoY, P/E 29.1. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (TTM) | $1.40B |
| Net Margin | 22.7% |
| Revenue Growth (YoY) | 47.7% |
| EPS Growth (YoY) | 44.1% |
| FCF Growth (YoY) | 141.2% |
| P/E Ratio | 29.1 |
| EV / EBITDA | 22.9 |
| Price / Book | 83.92 |
| Price / Sales | 7.24 |
| FCF Yield | 6.7% |
| DCF Value (model) | $13.66 |
| DCF Upside vs Price | -87.1% |
| Altman Z-Score | 4.54 (safe) |
| Piotroski F-Score | 5/9 |
| Sector P/E (Healthcare) | 21.6 |
HALO overview · HALO earnings · HALO KPIs · HALO investor relations · HALO ownership · HALO peers · HALO filings
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.